Diversified Trust Co Increases Position in Novo Nordisk A/S (NYSE:NVO)

Diversified Trust Co lifted its holdings in Novo Nordisk A/S (NYSE:NVO) by 13.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 3,246 shares of the company’s stock after buying an additional 395 shares during the quarter. Diversified Trust Co’s holdings in Novo Nordisk A/S were worth $279,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently modified their holdings of NVO. Strategic Investment Solutions Inc. IL bought a new position in Novo Nordisk A/S in the 2nd quarter valued at $25,000. Abound Wealth Management grew its holdings in shares of Novo Nordisk A/S by 257.4% in the second quarter. Abound Wealth Management now owns 218 shares of the company’s stock worth $31,000 after purchasing an additional 157 shares during the last quarter. Daiwa Securities Group Inc. bought a new stake in Novo Nordisk A/S during the 3rd quarter valued at about $28,000. Capital Performance Advisors LLP purchased a new stake in Novo Nordisk A/S in the 3rd quarter valued at about $42,000. Finally, Carolina Wealth Advisors LLC bought a new position in Novo Nordisk A/S in the 3rd quarter worth about $48,000. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research firms have recently weighed in on NVO. BNP Paribas raised shares of Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. StockNews.com downgraded Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Sunday, December 29th. BMO Capital Markets cut their price target on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research note on Monday, December 23rd. Finally, UBS Group upgraded shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company has an average rating of “Buy” and an average target price of $140.20.

Novo Nordisk A/S Price Performance

Shares of NVO stock opened at $86.41 on Friday. The stock’s 50-day moving average is $100.35 and its 200 day moving average is $119.21. Novo Nordisk A/S has a 1-year low of $81.50 and a 1-year high of $148.15. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75. The company has a market cap of $387.77 billion, a P/E ratio of 27.96, a PEG ratio of 1.37 and a beta of 0.45.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.